The Center for Biosimilars® recaps the top 5 articles for the week of May 14, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 14.
Number 5: The President’s plan to reduce drug prices for Americans includes asking FDA to issue guidance on possible abuse of safety programs to delay generic or biosimilar competition.
Number 4: Pfenex has announced positive top-line results from a phase 3 study of its follow-on teriparatide, referencing Forteo, a recombinant human parathyroid hormone.
Number 3: A study of pregnant patients treated with biosimilar infliximab for inflammatory bowel disease found that the biosimilar was not associated with any new safety concerns.
Number 2: CMS has released updated versions of its Drug Spending Dashboards, and data included show that prices are on the rise for drugs that have existing or upcoming biosimilar competition.
Number 1: The FDA has approved Pfizer’s epoetin alfa biosimilar, Retacrit, which the company is preparing to launch in 2018.
Finally, last week, our e-newsletter asked for your thoughts on which approach to biosimilar education is likely to have the biggest impact.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.